Abstract:Background and purpose: Gene transfer with recombinant non-viral vectors encoding vasodilator proteins, Such as endothelial nitric oxide synthase (eNOS), may be a preferential choice in gene therapy of artery restenosis following angioplasty, stent or anastomosis. However, the transfection rate of a non-viral vector, the harmful effects of eNOS transfection on endothelial cells (EC)and the control release of nitric oxide (NO) have been controversial. We designed the eukaryotic expression vector pcDNA3.1-eNOS to study the regulated expression of eNOS (in the presence of various chemical agents) and to evaluate the exogenous NO effect on EC proliferation in vitro.Methods: The full-length human eNOS cDNA was inserted into the EcoRI cloning site of the pcDNA3.1 expression plasmid and the eNOS direction was tested by restriction enzyme digestion with XhoI to construct recombinant pcDNA3.1-eNOS. After co-transfection of pcDNA3.1-eNOS with pcDNA3.0-EGFP mediated by cationic liposomes into Human umbilical vein endothelial cells (ECV304), the transfection rate and the effect on ECV304 proliferation were calculated by fluorescence microscopy and flowcytometry. eNOS mRNA and protein were detected by reverse transcription-PCR (RT-PCR) and immunofluorescence, respectively. The eNOS activity, NO release and changes of the relevant cells growth curve were assessed after treating the transfected cells with four independent factors including ie Ca2+, L-arginine (L-Arg), Ethylene Diamine Tetraacetic Acid (EDTA) and N-nitro-L-arginine methylester (L-NAME). In addition, we examined the nontransfected cells status by isolated sodium nitroprusside (SNP) treatment.Result: eNOS cDNA was inserted into pcDNA3.1 in die proper direction. RT-PCR analysis showed that pcDNA3.1-eNOS transfected cells could express eNOS mRNA. The rate of eNOS transfection was 39.6 +/- 3.4%. Immunofluorescence staining displayed that subcellular localisation of eNOS was most prominent in plasma membrane and per] nuclear regions of the cell. The eNOS activity of eNOS transfected cells had not increased significantly, whereas, in the presence of Call, L-Arg, EDTA, and L-NAME, the eNOS activity was 96.98 +/- 13.47, 32.57 +/- 6.39, 11.63 +/- 3.02, 15.56 +/- 7.34 U/ml respectively and the NO level was 55.34 +/- 11.19, 9.43 +/- 4.51., 2.63 +/- 1.41, 3.73 +/- 1.65 mmol/L, respectively. Meanwhile, die growth curves of EC shifted. SNP also had obvious growth-inhibiting effects on the cells. Together, the ECV304 growth curve went downward in a NO concentration-dependent manner.Conclusion: Eukaryotic expression vector pcDNA3.1-eNOS was constructed successfully with the ability to express human eNOS mRNA and protein in EC effectively. The activity of eNOS in EC could be regulated by certain exogenous factors. Ca2+ was an important factor promoting NO release and excess NO had a cytotoxic effect on EC in vitro. Controlled release of NO in vivo and polygenic measurements might be considered in more clinical gene therapy studies.

Adenovirus Gene Transfer Of Recombinant Endothelial Nitric Oxide Synthase Enhances Contractile Function In Ventricular Myocytes

Raav-Mediated Angiogenin Gene Transfer Induces Angiogenesis and Modifies Left Ventricular Remodeling in Rats with Myocardial Infarction

Optimization of Adenovirus-Mediated Endothelial Nitric Oxide Synthase Delivery in Rat Hindlimb Ischemia

Angiogenin Gene Transfer Improves Left Ventricular Function in Rats with Myocardial Infarction

Inhibition of MAPK signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through reduction of inflammation

Experimental Study of Recombinant Aukaryotic Expression Vector of Human Enos in ECV304 Cells

Adventitial Expression of Recombinant Endothelial Nitric Oxide Synthase Gene Reverses Vasoconstrictor Effect of Endothelin-1

[Dynamin-Mediated Endocytic Process Contributes to Neuronal Nitric Oxide Synthase-Mediated Regulation of Cardiac Contraction].

Effects of Adenovirus-Mediated Endothelial Nitric Oxide Synthase Gene Transfer on Neointimal Proliferation of Rat Carotid Artery after Balloon Injury

Construction of the Recombinant Human Endothelial Nitric Oxide Synthase Gene Adenovirus and Its Expression in Human Vascular Smooth Muscle Cells

Effect of Endothelial Nitric Oxide Synthase on Proliferation of Rat Vascular Smooth Muscle Cells from Ballon-Injured Carotid Artery

The role of MAPK in the cardioprotective effects of eNOS gene transfection after myocardial infarction

Cardiac-specific gene expression facilitated by an enhanced myosin light chain promoter.

Activation of endothelial nitric oxide synthase is dependent on its interaction with globular actin in human umbilical vein endothelial cells

Endothelial nitric oxide synthase expression in endothelial cells following aukaryotic expression vector construction

Deterioration of cardiac function after acute myocardial infarction is prevented by transplantation of modified endothelial progenitor cells overexpressing endothelial NO synthases.

S100A1 gene transfer in myocardium

Gene transfer of endothelial nitric oxide synthase attenuates flow-induced pulmonary hypertension in rabbits.

S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts

Gene Transfer of Human Endothelial Nitric Oxide Synthase Inhibits Proliferation of Human Vascular Smooth Muscle Cells and the Mechanism

Mesenchymal Stem Cells with Enos Over-Expression Enhance Cardiac Repair in Rats with Myocardial Infarction